Lung Adenocarcinoma, Lung Cancer, Lung Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
Conditions
Keywords
Lung cancer, Surgery, Real world
Brief summary
This study is a multi-center, observational, real-world study for patients with resected lung cancers in China. With the help of a properly designed data processing algorithm and extensively performed data quality assurance, this study aims to harness the potential of real-world big data to (1) describe characteristics and treatment patterns and their evolving trends; (2) discover features associated with overall survival; and (3) address recently-emerging clinical questions.
Detailed description
Lung cancer is the leading cause of cancer-related deaths in China. The recent decade witnessed rapid evolving of demographics, pathological features and prognoses of patients with surgically resected lung cancers. The introduction of minimally invasive surgery (MIS) concept and techniques, targeted therapy and immunotherapy changed treatment landscape for patients with surgically resected lung cancers. With more early-stage lung cancers discovered due to the application of CT screening, questions focusing on extent of lung resection, lymph node dissection, application of targeted or immune-therapy to early-stage lung cancers are emerging. This study aims to create a cohort of patients with surgically resected lung cancers and an analytic framework to address the aforementioned clinical questions.
Interventions
None listed
Sponsors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age above 18. * Have received surgical resection for lung malignancies.
Exclusion criteria
* Participants whose data are of low quality, poor completeness or poor internal linkage.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | January 2014 to December 2031 | Time from surgery to death from any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Baseline characteristics of included participants | January 2014 to December 2028 | Demographics, symptoms at diagnosis, tobacco exposure, family history, previous medical history, etc. |
| Treatment patterns of included participants | January 2014 to December 2028 | Extent of lung resection and lymph node dissection, application of certain surgical techniques or not; application of chemotherapy, targeted therapy, immunotherapy and/or radiotherapy before and/or after surgery. |
| Pathological characteristics of included participants | January 2014 to December 2028 | Location, size, classification, presence or absence of certain pathological features of resected tumor(s); number of metastasized and dissected lymph nodes in each station. |
| Features associated with overall survival | First analysis is anticipated to be performed from April to August 2024; the final analysis is anticipated in 2032. | Features within the range of collected baseline characteristics, treatment patterns and pathological characteristics that are associated with overall survival. |
Countries
China
Contacts
Primary ContactFengwei Tan, MD-PhD
Backup ContactRenda Li, MD
Outcome results
None listed